Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/106888
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCostello, S.en
dc.contributor.authorSoo, W.en
dc.contributor.authorBryant, R.en
dc.contributor.authorJairath, V.en
dc.contributor.authorHart, A.en
dc.contributor.authorAndrews, J.en
dc.date.issued2017en
dc.identifier.citationAlimentary Pharmacology and Therapeutics, 2017; 46(3):213-224en
dc.identifier.issn0269-2813en
dc.identifier.issn1365-2036en
dc.identifier.urihttp://hdl.handle.net/2440/106888-
dc.description.abstractBackground: Faecal microbiota transplantation (FMT) is emerging as a novel therapy for ulcerative colitis (UC). Interpretation of efficacy of FMT for UC is complicated by differences among studies in blinding, FMT administration procedures, intensity of therapy and donor stool processing methods. Aim: To determine whether FMT is effective and safe for the induction of remis- sion in active UC. Methods: Medline (Ovid), Embase and the Cochrane Library were searched from inception through February 2017. Original studies reporting remission rates follow- ing FMT for active UC were included. All study designs were included in the sys- tematic review and a meta-analysis performed including only randomised controlled trials (RCTs). Results: There were 14 cohort studies and four RCTs that used markedly different protocols. In the meta-analysis of RCTs, clinical remission was achieved in 39 of 140 (28%) patients in the donor FMT groups compared with 13 of 137 (9%) patients in the placebo groups; odds ratio 3.67 (95% CI: 1.82-7.39, P< .01). Clinical response was achieved in 69 of 140 (49%) donor FMT patients compared to 38 of 137 (28%) placebo patients; odds ratio 2.48 (95% CI: 1.18-5.21, P=.02). In cohort studies, 39 of 168 (24%; 95% CI: 11%-40%) achieved clinical remission. Conclusions: Despite variation in processes, FMT appears to be effective for induc- tion of remission in UC, with no major short-term safety signals. Further studies are needed to better define dose frequency and preparation methods, and to explore its feasibility, efficacy and safety as a maintenance agent.en
dc.description.statementofresponsibilityS. P. Costello, W. Soo, R. V. Bryant, V. Jairath, A. L. Hart, J. M. Andrewsen
dc.language.isoenen
dc.publisherWileyen
dc.rights© 2017 John Wiley & Sons Ltd.en
dc.subjectFeces; Humans; Colitis, Ulcerative; Remission Induction; Randomized Controlled Trials as Topic; Fecal Microbiota Transplantationen
dc.titleSystematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitisen
dc.typeJournal articleen
dc.identifier.rmid0030072156en
dc.identifier.doi10.1111/apt.14173en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1085080en
dc.identifier.pubid357365-
pubs.library.collectionPharmacology publicationsen
pubs.library.teamDS10en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidCostello, S. [0000-0002-2857-1812]en
dc.identifier.orcidBryant, R. [0000-0003-4229-3289]en
dc.identifier.orcidAndrews, J. [0000-0001-7960-2650]en
Appears in Collections:Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.